Transplant

The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.

Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie

Allogeneic Transplant

Regimen Name Indication

Busulfan/cycloPHOSphamide–MAC–MUD

Regimen

00639a

Myeloablative conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.

Busulfan/cycloPHOSphamide – MAC – SIB

Regimen

00641a

Myeloablative conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.

Busulfan/cycloPHOSphamide/ATG Grafalon® – MAC – Mismatched Sibling Donor

Regimen

00662a

Myeloablative conditioning for mismatched sibling donor allogeneic stem cell transplant in patients with myeloid disorders.

Busulfan/cycloPHOSphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor

Regimen

00663a

Myeloablative conditioning for mismatched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.

Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD

Regimen

00638a

Reduced intensity conditioning for sibling or matched unrelated allogeneic stem cell transplantation in Hodgkins and Non-Hodgkin's Lymphoma.

Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD

Regimen

00631a

Myeloablative conditioning (MAC) for matched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.

Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB

Regimen

00637a

Myeloablative conditioning (MAC) for sibling donor allogeneic stem cell transplant in patients with lymphoid disorders.

Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor

Regimen

00630a

Myeloablative conditioning (MAC) for mismatched sibling donor allogeneic stem cell transplant in patients with lymphoid disorders.

Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor

Regimen

00629a

Myeloablative conditioning (MAC) for mismatched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.

Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD

Regimen

00635a

Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.

Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB

Regimen

00636a

Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.

 Fludarabine/ Melphalan with-post transplant cycloPHOSphamide Therapy

Regimen

00868a

Reduced Intensity Conditioning with Fludarabine and Melphalan for Mismatched Unrelated Donors or physician choice for myeloid and lymphoid malignancies.

Fludarabine/Melphalan/Alemtuzumab-RIC-MUD

Regimen

00625a

Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with lymphoproliferative disorders. 

Fludarabine/Melphalan/Alemtuzumab-RIC-SIB

Regimen

00611a

Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with lymphoproliferative disorders.

Fludarabine/Busulfan (FluBu4) – with post-transplant cycloPHOSphamide Therapy (PTCy)

Regimen

 00910a

Myeloablative conditioning with fludarabine and busulfan for matched and mismatched donor with peripheral blood stem cells (PBSC)
 

Fludarabine/Busulfan (FluBu2) – with post-transplant cycloPHOSphamide Therapy (PTCy)

Regimen

  00911a

Reduced intensity conditioning with fludarabine and busulfan for matched and mismatched unrelated donor and peripheral blood stem cells (PBSC)
 

Fludarabine and Total Body Irradiation (Flu/TBI) with post-transplant cycloPHOSphamide Therapy (PTCy)

Regimen

  00913a

Acute lymphoblastic leukaemia (ALL), myeloablative conditioning (MAC) with peripheral blood stem cell (PBSC) or mismatched donor

Autologous Transplant

Regimen Name Indication

BEAM Autologous Transplant Conditioning Protocol

Regimen

00408a

Autologous conditioning in non-Hodgkin's Lymphoma (NHL).

00408b

Autologous conditioning in Hodgkins Lymphoma.

LEAM Autologous Transplant Conditioning Protocol

Regimen

00468a

Autologous conditioning in non-Hodgkin's Lymphoma (NHL).

00468b

Autologous conditioning in Hodgkins Lymphoma.

High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant

Regimen

00454a 

Conditioning Therapy in patients with Multiple Myeloma prior to autologous stem cell transplant.

00454b

Conditioning Therapy in patients with other plasma cell dyscrasia such as AL amyloidosis.